1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,800 | 9,900 | 22:52 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 19.02. | Devyser Diagnostics AB: Devyser secures a major SEK 16.8M tender in Italy with 30% growth | 119 | GlobeNewswire (Europe) | Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers.... ► Artikel lesen | |
| 13.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2024 | 181 | GlobeNewswire (Europe) | "Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust development... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK | 94 | GlobeNewswire (Europe) | Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK
"This... ► Artikel lesen | |
| 16.01. | Devyser Diagnostics AB: Devyser publishes preliminary result for Q4 2024 | 619 | GlobeNewswire (Europe) | In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before... ► Artikel lesen | |
| 30.10.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2024 | 100 | GlobeNewswire (Europe) | "It is very gratifying to see the impact that we are having in the field of diagnostics. I have just returned from the ASHI event, a major transplantation conference in the US, and it is clear that... ► Artikel lesen | |
| 23.07.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2024 | 121 | GlobeNewswire (Europe) | "Devyser continued to report high sales growth in the second quarter. Organic growth compared with the same quarter of last year amounted to 41 percent in SEK. We won several large tenders during the... ► Artikel lesen | |
| 08.05.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2024 | 116 | GlobeNewswire (Europe) | "Devyser reports continued strong sales growth and high gross margins for the quarter. It is particularly pleasing to see that our investment in the Americas is continuing to produce results, with growth... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 83,92 | -0,43 % | Medtronic reports first real-world data on smart insulin pen system | ||
| HCA HEALTHCARE | 305,00 | -0,55 % | Dividendenbekanntmachungen (17.03.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALTAGAS LTD CA0213611001 0,315 CAD 0,2014 EUR AMERICAN FINANCIAL GROUP INC US0259321042 2 USD 1,8382 EUR AMERICAN INTERNATIONAL... ► Artikel lesen | |
| AMEDISYS | 85,50 | +0,59 % | Amedisys, Inc.: Amedisys Reports Fourth Quarter and Year End 2024 Financial Results | BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2024. Three-Month Periods... ► Artikel lesen | |
| LANTHEUS | 92,02 | -2,85 % | AKTIONÄR-Tipp Lantheus: Telix-Rivale geht nach Zahlen durch die Decke | Der Radiopharma-Spezialist Lantheus kann am Donnerstag mit den Zahlen zum vierten Quartal respektive Gesamtjahr 2024 und dem Ausblick auf das laufende Jahr 2025 überzeugen. Die Aktie des Wettbewerbers... ► Artikel lesen | |
| ENVISTA | 15,500 | -0,64 % | Envista: DEXIS Showcases Newest Technology at Chicago Midwinter and Lab Day Conferences | The global leader in dental imaging technologies will showcase the latest innovations added to its digital ecosystem - a suite of tools and software designed to connect the entire digital workflow from... ► Artikel lesen | |
| CAREDX | 17,325 | -1,31 % | CareDx, Inc.: CareDx gibt Studie bekannt, die zeigt, dass AlloSeq cfDNA bei der Erkennung von Abstoßungsreaktionen bei Organtransplantationspatienten äußerst genau ist | AlloSeq cfDNA entspricht der Leistung des bewährten AlloSure-Tests CareDx bringt mit AlloSeq cfDNA ein innovatives nicht-invasives Transplantationsmonitoring für Patienten auf internationaler... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fiscal Second Quarter 2025 Results | Reports 23 Percent Increase in ARR to $19.1 Million and 61 Net New Platform Deployments HENDERSON, Nev., Feb. 13, 2025 /PRNewswire/ -- Research Solutions, Inc. (NASDAQ: RSSS), the leading... ► Artikel lesen | |
| GT BIOPHARMA | 2,390 | -1,65 % | GT Biopharma, Inc.: GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit | ||
| CARMAT | 0,876 | +2,34 % | CARMAT: Aeson total artificial heart highlighted as a very promising solution for heart failure patients with pulmonary hypertension in The Journal of Heart and Lung Transplantation | Up to 25% of advanced heart failure patients suffer from pulmonary hypertension
Aeson® could potentially become a standard treatment for these thousands of patients, both as a bridge-to-transplant... ► Artikel lesen | |
| CHEMOMETEC | 71,65 | -0,83 % | Chemometec A/S: Interim report 2024/25 - Solid H1 performance driven by growth in both revenue and earnings | ANNOUNCEMENT NO. 2875 February 2025 Solid H1 performance driven by growth in both revenue and earnings Martin Helbo Behrens, CEO: The growth continued in the second quarter of 2024/25, and revenue... ► Artikel lesen | |
| HAMILTON THORNE | 1,490 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.12.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 02.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.12.2024ISIN NameCA81012R1064 SCOTTIE... ► Artikel lesen | |
| ARRAIL GROUP | 0,218 | +9,55 % | ARRAIL GROUP (06639): 2024/2025 INTERIM REPORT | ||
| POLAREAN IMAGING | 0,010 | +1.800 % | Polarean Imaging PLC - Expansion of Xenon MRI imaging platform | ||
| PROMIMIC | 2,350 | -4,86 % | Karolinska Development AB (publ): Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface | STOCKHOLM, SWEDEN, February 18 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic has published positive results showing a reduction of bacterial... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 51,42 | -2,61 % | EQS-CMS: Siemens Healthineers AG: Bekanntmachung nach Art. 5 Abs. 1 lit. a) der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung (EU) Nr. 2024/2809 (MAR) i.V.m. Art. 2 Abs. 1 der Delegierten Verordnung (EU) Nr. 2016 | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation
Bekanntmachung nach... ► Artikel lesen |
Das Unternehmen DEVYSER DIAGNOSTICS AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 9,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.
